This is an old revision of this page, as edited by Pashihiko (talk | contribs) at 06:08, 14 January 2011. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:08, 14 January 2011 by Pashihiko (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C29H38FN3O3 |
| Molar mass | 495.63 g/mol g·mol |
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
It is nonselective.
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, due to the potential for drug interactions, some of them serious, which may occur when it is taken together with some other medications.
References
- Bezprozvanny I, Tsien RW (1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
{{cite journal}}: Unknown parameter|month=ignored (help) - Letter from Roche Laboratories: http://www.fda.gov/medwatch/SAFETY/1998/poscor.htm
 | This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it. |